University Research Commercialisation

The Australian Government is undertaking a scoping study to understand how to best implement a University Research Commercialisation Scheme to better translate and commercialise university research outputs. It has appointed an Expert Panel and issued a Discussion Paper.

Research Australia’s response to the Discussion Paper addresses the role of ‘Missions’, the use of stage-gating and the role of co-funding by Governments, universities and industry. It highlights the critical need to better align existing funding programs and fill the gaps to provide a more seamless approach to research funding from basic research through to commercialisation.

Research Australia’s submission is available here.

Critical Technologies Consultation

The Australian Government’s Critical Technologies Policy Coordination Office is identifying critical current and emerging technologies with the capacity to significantly enhance or pose risk to Australia’s national interest, including our economic prosperity, social cohesion and national security. One of the key areas identified is health.

Research Australia’s submission to the consultation on health related technologies has emphasised the opportunity to address supply chain issues in the development and manufacturing of new technologies in Australia.  Research Australia’s submission is available here.

Better Use of Commonwealth Data

The Data Availability and Transparency Bill is intended to improve researcher access to datasets held by Commonwealth Government Departments and Agencies.  Its introduction to Parliament follows a three year consultative development process triggered by recommendations for legislative reform contained in the Productivity Commission’s report on the Availability and Use of Commonwealth Government Data. The Bill is the subject of an Inquiry by a Senate Committee.

Research Australia has been closely engaged with the development of the Bill and is supportive of its passage through Parliament. Our submission includes case studies of the public benefits that can be achieved from the use of health data, and the current barriers to access and use of data.

Research Australia’s submission is available here.

 

Response to Health Department Consultation on Productivity Commission Recommendations on Mental Health

Having commissioned an Inquiry into mental health by the Productivity Commission, the Australian Government Department of Health and Ageing has now undertaken a consultation on the recommendations contained in the Commission’s final report.

The Consultation was undertaken using an electronic survey, which has restricted the response to each question to a maximum of 500 words. Research Australia’s response to each of the questions posed by the survey is provided in our submission. Our responses emphasise:

    • the critical role of research in supporting the evaluation of existing programs and measures and the development and implementation of new programs;
    • the need to focus on implementation and scalability as part of translating research findings into new and effective preventive mental health programs; and
    • the essential role of data in evaluating the effectiveness of programs and the performance of the mental health system as a whole.

Research Australia acknowledges the contribution of our members to this submission, especially Black Dog Institute, Orygen, SANE Australia and Beyond Blue.

2021 Pre Budget submission calls for renewed investment in R&D

Research Australia’s Pre Budget submission to the Treasurer ahead of the 2021 Budget  focuses on the vital role of health and medical research and innovation in Australia’s  response to the COVID-19 pandemic, and the manufacturing and innovation opportunities that health and medical research presents for Australia’s economic recovery.

It calls for renewed investment in R&D by the Australian Government, continued support for universities and medical research institutes with meeting indirect research costs, and measures to support medical products R&D and manufacture. The case for increasing NHMRC and ARC funding is also made. Funding for Government initiatives in data sharing and preventive health are among other measures sought.

Research Australia’s submission is available here.

Research to improve Aged Care quality

Counsel assisting the Aged Care Royal Commission have made their final submissions to the Commissioners, and the public has been given the opportunity to comment on the recommendations. This was the last chance for public input before the Commissioners provide their report to the Government in early 2021.

Research Australia has followed the progress of the Royal Commission closely. We urged the inclusion of research in the Commission’s original terms of reference and we have liaised with the Commission’s officers to connect them with researchers who were able to assist the Inquiry.

We have been pleased to see the reliance the Commission has placed on research to understand the current system and its failures as well as to explore alternatives. It is clear that research can play a critical part in improving the delivery of aged care services and in helping Australians to age well, and we have welcomed the prominence the final recommendations to the Commissioners give to research.

Research Australia’s response to the final submissions document is limited to two recommendations. Recommendation 55 deals with the creation of an Aged Care Research Council with a dedicated research budget. Recommendation 56 deals with creation of a minimum national aged care dataset and the availability of data to researchers. Finally, we have responded to the request for public response to remarks made by Commissioner Briggs in respect of Research and Data Governance.

Research Australia’s submission is available here.

Medical Products Roadmap Consultation

Research Australia has responded to the consultation being undertaken by the Department of Industry, Science, Energy and Resources to support the development of a Medical Products Manufacturing Roadmap under the Modern Manufacturing Initiative announced in the October 2020 Budget. Medical products is one of six strategic areas being targeted under the MMI for Government spending of $1.3 billion over five years.

The Consultation was undertaken using an electronic survey restricted the length of the response to each question. Research Australia’s response emphasises:

    • the opportunity to support the manufacture of products and materials for clinical trials;
    • the opportunity this provides to scale to full scale manufacturing, keeping the full scale manufacturing of medical products developed in Australia on shore; and
    • the opportunity to support manufacturing in high value medical products.

Research Australia’s submission is available here.  These proposals were further developed in Research Australia’s January 2021 Pre Budget submission, available here.

The Government subsequently released the Medical Products National Manufacturing Priority Roadmap in February 2021. Research Australia’s proposal to support manufacturing for clinical trials as part of the Roadmap was adopted, and identified as a pathway to scaling up of manufacturing capability. The Roadmap is available here.

Data Availability and Transparency- Draft Bill and Accreditation Framework

Research Australia has been advocating for many years for improved access to public data for research. We made submissions to the Productivity Commission’s 2016 Inquiry into Data Availability and Use. Strongly supportive of the Commission’s recommendations, we have worked with the Department of Prime Minister and Cabinet on the consultations which have culminated in the release of the Data Availability and Transparency Bill exposure draft and the proposed Accreditation Framework.

The Draft Bill and accompanying Accreditation Framework for researchers are broadly in line with previous consultations and discussions. Research Australia has made some recommendations designed to improve the operation of the legislation and the Framework.

Research Australia’s submission is available here.

The Data Availability and Transparency Bill was introduced into the House of Representatives on 9 December 2020. Research Australia expects the legislation to be passed by the Parliament in 2021.

Improving approval processes for new drugs and medical technologies

Research Austrlaia has responded to the Parliamentary Inquiry into the Approval Processes for New Drugs and Medical Technologies.

Opportunities exist to change our approval processes to benefit patients and better support research and development in Australia. Faster and more effective approval processes mean new medicines and technologies reach patients faster. Improving the environment for clinical trials enables Australian patients to benefit from the latest medicines and technologies developed overseas while also helping Australian health and medical research to flourish in a competitive and lucrative world market. Research Australia’s submission identifies some of these opportunities with the twin objectives of improving Australians’ health and prosperity.

Research Austrlaia’s submission is available here.

The Committee is expected to hold public hearings in early 2021.

Research for Preventive Health

The Australian Government is developing a 10-year National Preventive Health Strategy, anticipated to be finalised and released in early 2021.

The Consultation has been undertaken using an electronic survey. Research Australia’s responses emphasise:

    • the critical role of research in developing new preventive health measures;
    • the need to focus on implementation and scalability as part of translating research findings into new and effective preventive health programs; and
    • the critical role of data in evaluating the effectiveness of programs.

Research Australia’s submission is available here.